Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression.

about

Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression.

Item

http://www.wikidata.org/entity/Q48115202

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Prostate-specific antigen decl ...... -specific antigen progression.

@en

Prostate-specific antigen decl ...... -specific antigen progression.

@nl

type

Item

label

Prostate-specific antigen decl ...... -specific antigen progression.

@en

Prostate-specific antigen decl ...... -specific antigen progression.

@nl

prefLabel

Prostate-specific antigen decl ...... -specific antigen progression.

@en

Prostate-specific antigen decl ...... -specific antigen progression.

@nl

P1476

Prostate-specific antigen decl ...... e-specific antigen progression

@en

P2093

Cuma Aytekin

http://www.w3.org/2001/XMLSchema#string

Erdem Akbay

http://www.w3.org/2001/XMLSchema#string

Mesut Tek

http://www.w3.org/2001/XMLSchema#string

Murat Bozlu

http://www.w3.org/2001/XMLSchema#string

Pelin Özcan Kara

http://www.w3.org/2001/XMLSchema#string

Selahittin Çayan

http://www.w3.org/2001/XMLSchema#string

P2860

A Urologist's Personal View of Prostate Cancer

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis.

Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study.

The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients.

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer.

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.

P304

175-183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13685538.2017.1328675

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28531357

http://www.w3.org/2001/XMLSchema#string